Conditions: Type 2 Diabetes Patients
Keywords: multiple dose study in type 2 diabetes patients
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 48
Healthy volunteers: no

Brief summary:
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: PF-04620110 intervention 2: PF-04620110 intervention 3: Placebo
Intervention descriptions: intervention 1: 5 mg of PF-04620110 given once daily intervention 2: 2.5 mg of PF-04620110 given twice daily intervention 3: Matching placebo giving for 4 weeks

Protocol document: